Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

Pomalidomide (Pom) has demonstrated synergistic antiproliferative activity in combination regimens as a result of its distinct anticancer, antiangiogenic, and immunomodulatory effects. This review aimed to compare outcome measures of different Pom regimens for relapsed/refractory multiple myeloma. A...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2019-07, Vol.19 (7), p.447-461
Hauptverfasser:	Mushtaq, Adeela, Iftikhar, Ahmad, Hassan, Hamza, Lakhani, Midhat, Sagar, FNU, Kamal, Ahmad, Zahid, Umar, Ali, Zeeshan, Razzaq, Faryal, Zar, Muhammad Abu, Hassan, Syeda Fatima, Safdar, Ahmad, Raychaudhuri, Sreejata, Anwer, Faiz
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse event Immunomodulator Outcome Overall response Pom-dex
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!